2026-06-03T20:51:15Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/288622026-02-03T10:57:44Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Doña, Inmaculada author Torres-Jaén, María Josefa author Gulfem, Celik author Phillips, Elizabeth author Kase Tanno, Luciana author Castells, Mariana author 2023-12-12 Drug allergy (DA) remains a complex and unaddressed problem worldwide that often deprives patients of optimal medication choices and places them at risk for life-threatening reactions. Underdiagnosis and overdiagnosis are common and due to the lack of standardized definitions and biomarkers. The true burden of DA is unknown, and recent efforts in data gathering through electronic medical records are starting to provide emerging patterns around the world. Ten percent of the general population engaged in health care claim to have a DA, and the most common label is penicillin allergy. Up to 20% of emergency room visits for anaphylaxis are due to DA and 15%–20% of hospitalized patients report DA. It is estimated that DA will increase based on the availability and use of new and targeted antibiotics, vaccines, chemotherapies, biologicals, and small molecules, which are aimed at improving patient's options and quality of life. Global and regional variations in the prevalence of diseases such as human immunodeficiency virus and mycobacterial diseases, and the drugs used to treat these infections have an impact on DA. The aim of this review is to provide an update on the global impact of DA by presenting emerging data on drug epidemiology in adult and pediatric populations. Doña I, Torres MJ, Celik G, Phillips E, Tanno LK, Castells M. Changing patterns in the epidemiology of drug allergy. Allergy. 2023;00:1-16. doi:10.1111/all.15970 https://hdl.handle.net/10630/28862 10.1111/all.15970 Epidemiología Changing patterns in the epidemiology of drug allergy